(Alliance News) - Rapid test developer and manufacturer Abingdon Health PLC on Friday said it has signed an exclusive manufacturing agreement with BioSure Ltd.
Shares in Abingdon Health were up 7.1% at 43.39 pence each in London on Friday morning.
BioSure is a Nazeing, Essex-based company specialising in the provision of rapid in-vitro diagnostic testing solutions.
Under the terms of the exclusive agreement, Abingdon will manufacture BioSure's own lateral flow tests in the field of Covid-19. The contract manufacturing services will utilise lateral flow manufacturing facilities at Abingdon's York and Doncaster sites.
"We are delighted to be supporting BioSure and building on our long-term collaboration with the BioSure team. We are committed to supporting the deployment of these much needed lateral flow test to the UK and international markets," said Abingdon Health Chief Executive Chris Yates.
By Amrit Sahota; newsroom@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Abingdon Healt. (ABDX)